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were taken in a motorized water phantom using small 
detectors (Razor stereotactic diode and PFD, IBA Dosimetry). 
In addition, MLC transmission was measured using a Farmer 
ion chamber. MLC model parameters (transmission, offset, 
leaf tip width, tongue-and-groove) were optimized to 
maximize the agreement between measurements and 
calculations. Model assessment was performed using a set of 
highly intensity-modulated MLC geometrical patterns, 
designed to enhance tongue-and-groove, transmission and 
offset/leaf-tip effects. For those fields, planar dosimetry was 
carried out with GafChromic EBT3 films. Clinical validation 
was performed evaluating TG-119 cases along with 25 DMLC 
and 10 VMAT clinical plans. Plan-specific quality assurance 
was performed with a 2D-array (MatriXX, IBA Dosimetry) and 
gamma-index metric was used to assess the agreement 
between planned and measured dose distributions. A 
2%/2mm criterion was used with both local (LN) and global 
(GN) normalization. 
 
Results: Optimized MLC parameters were: transmission 
0.018, position-offset 0.04cm, tongue-and-groove 0.05cm, 
leaf tip width 0.3cm. Average and standard deviation (SD) 
values of gamma index pass-rates were: for geometrical 
patterns: 92.8%, SD=5.1%(LN); 95.5%, SD=2.5%(GN). For TG-
119 plans: 97.1%, SD=4.4%(LN); 99.7%, SD=0.7%(GN). For 
DMLC clinical plans: 97.0%, SD=3.7% (LN); 98.8%, 
SD=2.6%(GN). For VMAT plans 90.1%, SD=4.0% (LN); 96.5%, 
SD=2.1% (GN). Critical regions dominated by tongue-and-
groove and rounded-leaf-tip effect showed a very good 
agreement between measurements and calculations (see 
Fig.1). 
 
 
Conclusion: Results demonstrate the followed procedure 
leads to a proper optimization of the MLC model in 
RayStation, leading to clinically acceptable gamma index 
pass-rates. The needed additional measurements can be 
easily integrated as a subset of the standard measurements 
required for the commissioning of the RayStation TPS. 
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Purpose or Objective: To compare dose-volume metrics 
calculated with the four-dimensional (4D) Monte Carlo (MC) 
and three-dimensional (3D) dose evaluation systems in 
dynamic tumor tracking (DTT) irradiation for lung or liver 
tumors. 
 
Material and Methods: Twenty patients with lung tumors and 
15 patients with liver tumors who underwent DTT irradiation 
using a gimbal-mounted linac were enrolled in this study. 
During computed tomography (CT) simulation, 4DCT under 
free breathing and exhale breath-hold CT were performed. 
Planning target volume (PTV) for DTT was calculated using 
the gross tumor volume (GTV) delineated on a reference CT 
scan (exhale phase in the 4DCT or exhale breath-hold CT) by 
adding asymmetric margins to compensate for possible errors 
due to the DTT. The 6 to 9 non-coplanar ports of the 6-MV X-
ray were set to each PTV. Doses were calculated for the 
reference CT using a commercially available treatment 
planning system (TPS). At the same time, 4DMC dose 
evaluation was performed for 10 respiratory phases of 4DCT 
using an in-house dose calculation system based on the MC 
algorithm, considering the gimbal rotation. The doses 
calculated for 10 phases were accumulated using deformable 
image registration software for the lung tumor patients, 
whereas mean values of the dose-volume metrics were 
evaluated for the liver tumor patients. The difference 
between the doses calculated with 4DMC (4D doses) and 
those calculated for the reference CT scan with TPS (3D 
doses) were investigated for the following dose-volume 
metrics: the percentage of dose that covers 95% of the GTV 
(GTV D95), the max dose received by the spinal cord (Cord 
max), the percentage of lung volume that received more 
than 20 Gy and 5 Gy irradiation (Lung V20 and Lung V5, 
respectively) in patients with lung tumors, and the mean 
dose and percentage of liver volume that received more than 
20 Gy irradiation (Liver mean and Liver V20, respectively) in 
patients with liver tumors. 
 
Results: The mean values of the dose-volume metrics for the 
4D doses were as follows: 94.1% (range, 83.8–99.7%) GTV D95, 
9.7 Gy (range, 1.8–22.0 Gy) Cord max, 4.9% (range, 1.9–
13.7%) Lung V20, 19.2% (range, 7.2–30.7%) Lung V5, 10.0 Gy 
(range, 5.2–15.2) Liver mean,15.5% (range, 8.2–27.7%) Liver 
V20 The mean differences in the dose-volume metrics for the 
3D and the 4D doses were as follows: 0.5% (range, -7.4–4.8%) 
GTV D95, 0.1 Gy (range, -2.5–1.8 Gy) Cord max, 0.1% (range, 
-0.8–1.4%) Lung V20, 0.3% (range, -1.6–2.1%) Lung V5, 0.1 Gy 
(range, -1.6–1.1 Gy) Liver mean, and -1.0% (range, -1.7–3.1%) 
Liver V20. There were no statistical significant differences in 
these dose-volume metrics evaluated by paired t-test. 
 
Conclusion: The 3D doses calculated with TPS for the target 
tumor and organs at risk were almost equal to those 
calculated with 4DMC. 3D dose could be used as a 
substitution for 4DMC calculation. However, the dose to the 
spinal cord was underestimated by a maximum of 2.5 Gy. 
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